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IMPORTANCE Bipolar disorder (BD) overlaps schizophrenia in its clinical presentation and
genetic liability. Alternative approaches to patient stratification beyond current diagnostic
categories are needed to understand the underlying disease processes andmechanisms.
OBJECTIVE To investigate the association between common-variant liability for
schizophrenia, indexed by polygenic risk scores (PRSs), and psychotic presentations of BD.
DESIGN, SETTING, AND PARTICIPANTS This case-control study in the United Kingdom used
multinomial logistic regression to estimate differential PRS associations across categories of
cases and controls. Participants included in the final analyses were 4436 cases of BD from the
Bipolar Disorder Research Network. These cases were compared with the genotypic data for
4976 cases of schizophrenia and 9012 controls from the Type 1 Diabetes Genetics
Consortium study and the Generation Scotland study. Data were collected between January
1, 2000, and December 31, 2013. Data analysis was conducted fromMarch 1, 2016,
to February 28, 2017.
EXPOSURES Standardized PRSs, calculated using alleles with an association threshold of
P < .05 in the second Psychiatric Genomics Consortium genome-wide association study of
schizophrenia, were adjusted for the first 10 population principal components and
genotyping platforms.
MAIN OUTCOMES ANDMEASURES Multinomial logit models estimated PRS associations with
BD stratified by Research Diagnostic Criteria subtypes of BD, by lifetime occurrence of
psychosis, and by lifetimemood-incongruent psychotic features. Ordinal logistic regression
examined PRS associations across levels of mood incongruence. Ratings were derived from
the Schedules for Clinical Assessment in Neuropsychiatry interview and the Bipolar Affective
Disorder Dimension Scale.
RESULTS Of the 4436 cases of BD, 2966 (67%) were female patients, and themean (SD) age
at interviewwas 46 [12] years. Across clinical phenotypes, there was an exposure-response
gradient, with the strongest PRS association for schizophrenia (risk ratio [RR] = 1.94; 95% CI,
1.86-2.01), followed by schizoaffective BD (RR = 1.37; 95% CI, 1.22-1.54), bipolar I disorder
subtype (RR = 1.30; 95% CI, 1.24-1.36), and bipolar II disorder subtype (RR = 1.04; 95% CI,
0.97-1.11). Within BD cases, there was an effect gradient, indexed by the nature of psychosis.
Prominent mood-incongruent psychotic features had the strongest association (RR = 1.46;
95% CI, 1.36-1.57), followed bymood-congruent psychosis (RR = 1.24; 95% CI, 1.17-1.33) and
BDwith no history of psychosis (RR = 1.09; 95% CI, 1.04-1.15).
CONCLUSIONS AND RELEVANCE For the first time to date, a study shows a polygenic-risk
gradient across schizophrenia and BD, indexed by the occurrence and level of
mood-incongruent psychotic symptoms.
JAMA Psychiatry. doi:10.1001/jamapsychiatry.2017.3485
Published online November 22, 2017.
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A lthough classified as a discrete diagnostic category,1-3bipolardisorder (BD)overlapsconsiderablywithschizo-phrenia (SCZ) in both its clinical presentation4-13 and
genetic liability.14-22 Bipolar disorder is a phenomenologi-
cally heterogeneous construct, and within the diagnostic
category, individualswithBDmayhavequite different symp-
tom profiles. It has been proposed that this clinical heteroge-
neity indicates underlying etiological heterogeneity and that
the degree of clinical similarity between BD and SCZ reflects
overlappingalleles,whichselectively influencespecific, shared
clinical characteristics rather than the global risk for the
disorder.23-25
Delusions and hallucinations are common in BD,26,27
with approximately one-third of all psychotic features
judged to be mood incongruent.28,29 Mood-incongruent
psychotic features are associated with poor prognosis and
poor lithium response and are qualitatively similar to the
prototypic symptoms of SCZ,30-32 suggesting that BD with
psychosis and particularly mood-incongruent psychotic fea-
tures may specify a subgroup or stratum with stronger etio-
logical links to SCZ. Stratified linkage and candidate-gene
studies of BD associations with chromosomal regions and
genes implicated in SCZ show stronger effects in psychosis
and mood-incongruent subsamples,33-36 providing some
support for this causal heterogeneity hypothesis; however,
lack of consistency in earlier linkage and candidate-gene
studies renders the overall support weak.
Genome-wide association studies (GWAS) have found a
substantial polygenic component to both BD and SCZ
risks, with a large proportion of the disorders’ genetic vari-
ance explained by common alleles partially shared by the 2
disorders.20 This polygenic risk can be calculated for indi-
viduals with a single summary measure: the polygenic risk
score (PRS; with higher scores indicating a higher burden of
risk alleles), which allows us to examine the genetic basis of
symptom domains within and across the 2 disorders37-39
with greater power than do the historical linkage and
candidate-gene approaches. The PRS-SCZ differentiates BD
cases from controls,16,20 and there are differential PRS
associations across subtypes with schizoaffective bipolar
disorder (SABD) (an intermediate subtype characterized by
admixture of SCZ and BD symptoms) having a relatively
larger burden of SCZ risk, compared with other BD
subtypes.15,40 To date, lack of power in well-phenotyped
samples has hindered fine-scale examination of the
association of SCZ polygenic-risk with psychotic symp-
toms in BD.
This study aimed to examine the association between
polygenic liability for SCZ and psychotic presentations of
BD using the PRSs generated from the most powerful
SCZ-GWAS discovery set currently available.21 Measures rel-
evant to the occurrence and nature of psychotic symptoms
were considered. We hypothesized that BD with psychosis
would be associated with higher polygenic risk for SCZ and
that this association would be stronger when mood-
incongruent psychotic features were present, given their
phenotypic similarity to the psychotic symptoms of proto-
typic SCZ.
Methods
Sample Ascertainment
Bipolar Disorder Sample
In total,data from4436casesofBDwithdeepphenotypic infor-
mation,Europeanancestry,anddomicile intheUnitedKingdom
werecollectedbetweenJanuary1,2000,andDecember31,2013,
via theUKBipolarDisorderResearchNetworkusingrecruitment
methodsreportedpreviously.15,41,42Thesamplecontained1399
cases not included in previous publications of the Bipolar Dis-
orderResearchNetwork.15,40Allparticipantswereassessedusing
aconsistentprotocol,which includedtheSchedules forClinical
AssessmentinNeuropsychiatry(SCAN)interview43administered
by trained research psychologists and psychiatrists, with very
good to excellent interrater reliability for all domains of
psychopathology.44Using informationfromtheSCANinterview
and case note review, we completed the Operational Criteria
Checklist.45ResearchDiagnosticCriteria(RDC)3diagnoses,which
differentiate individualsonthebasisoftheirpatternofmoodand
psychotic symptomsbetter40 than either theDSM-52 or the In-
ternationalStatisticalClassificationofDiseasesandHealth-Related
Disorders,TenthRevisionClassificationofMentalandBehavioural
Disorders,1 were made with consensus lifetime best-estimate
methodinformedbyallavailable information.46TheBipolarDis-
orderResearchNetworkstudywasgivenafavorableethicalopin-
ionbytheWestMidlandsMulti-CentreResearchEthicsCommit-
tee. Local researchanddevelopment approvalwasobtained in
all participating National Health Service Trusts and Health
Boards. All participants gave written informed consent. Data
analysiswasconductedfromMarch1,2016,toFebruary28,2017.
Schizophrenia Sample
To allow the comparison of BD to SCZ, we included a subset
(n = 4976) of the CLOZUK (treatment-resistant schizophre-
nia, treated with clozapine) study sample collected via the
ZaponexTreatmentAccessSystem,whichwasdetailed inapre-
vious report.47Allpatients in thesamplewereprescribedcloza-
pine for treatment-resistant SCZ and are independent of and
unrelated (pi-hat <0.2) with individuals in the discovery
Key Points
Question What is the association between schizophrenia-related
polygenic liability and the occurrence and level of
mood-incongruence of psychotic symptoms in bipolar disorder?
Findings In this case-control study involving 4436 cases of
bipolar disorder, 4976 cases of schizophrenia, and 9012 controls,
there was an exposure-response gradient of polygenic risk.
Schizophrenia had the strongest association, followed by bipolar
disorder with prominent mood-incongruent psychotic features,
bipolar disorder with mood-congruent psychotic features, and
bipolar disorder with no psychosis; all differential associations
were statistically significant.
Meaning This study shows a gradient of genetic liability across
schizophrenia and bipolar disorder, indexed by the occurrence of
psychosis and level of mood incongruence.
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GWAS.21 Inprinciple, treatment-resistantSCZmaycarryhigher
polygenic risk burden; however, the PRSs in the CLOZUK
sample are similar to the PRSs in other SCZ samples used by
the Psychiatric Genomics Consortium.21 The CLOZUK proce-
dures and methods were approved by the National Research
Ethics and were in line with the UK Human Tissue Act regu-
lations in partnership with the Leyden Delta.
Control Samples
The controls came from 2 UK sources: (1) the Type 1 Diabetes
GeneticsConsortiumstudy,whichcomprisedunscreenedcon-
trols (n = 2532) recruited through the 1958BirthCohort,48 and
(2) a subsample (n = 6480) of the Generation Scotland study
screened for psychiatric disorders.49 Controls were not asso-
ciated (pi-hat <0.2)with individuals in thePsychiatricGenom-
ics Consortium-SCZ discovery set and were matched ances-
trally to our case data sets.47 The Generation Scotland Access
Committee approved this application to useGeneration Scot-
land as controls.
Genotyping, Quality Control, Phasing, and Imputation
Bipolar Cases
Genotypic data for the BD cases were processed in 3 batches,
eachonadifferentplatform.Tomitigate against potential bias
from batch effects,50 stringent quality control (QC) was per-
formed on each platform separately prior to merging. Single-
nucleotidepolymorphisms (SNPs)wereexcluded if thecall rate
was less than 98%, theminor allele frequency (MAF)was less
than0.01,or theSNPsdeviated fromtheHardy-Weinbergequi-
librium(HWE)atP < 1 × 10−6. Individualswereexcluded if they
had minimal or excessive autosomal homozygosity (F|>0.1),
high pairwise relatedness (pi-hat >0.2), or mismatch be-
tween recorded andgenotypic sex. FollowingQC, thedata for
eachplatformwerephasedusingSHAPEIT,51version3.4.0.1023
(OlivierDelaneau), and imputedwith IMPUTE2,52version2.3.0
(University of Oxford), using the 1000 Genomes Project ref-
erence panel (phase 3). Imputed datawere converted into the
most probable genotypes (probability >0.9) and merged on
shared SNPs. After QC, 4399 BD cases remained.
CLOZUK Cases and Controls
TheCLOZUKandcontrol sampleswent throughstrictQCsepa-
ratelybeforebeingphasedand imputedsimultaneouslyaspart
of a larger SCZ study.47
Merging Imputed Genotypic Data Sets
After SNPswith standambiguitywere excluded,BD,CLOZUK,
and control samples were merged and the imputed markers
underwenta secondQCfilter.50This secondQCexcludedSNPs
with amissingness rate ofmore than 5%of individuals, an in-
formation content score lower than 0.8, an MAF of less than
0.01, or deviation from HWE at P < 1 × 10−6.
Principal Component Analysis
Toadjust forpotential confounding frompopulationstructure,
weperformedprincipal components analysis.WeusedPLINK,
version 1.9 (Christopher Chang), after pruning the linkage dis-
equilibriumand frequency filtering the SNPs from themerged
sample, keeping theeigenvectors for the first 10principal com-
ponents to use as covariates in the association analysis.
Polygenic Risk Scores
We generated the PRSs20 using the 2014 Psychiatric Genom-
ics Consortium-SCZ meta-analysis as our discovery set21 cal-
culated for each individual on the basis of a set of alleles with
association P < .05. This decision was informed by the Psy-
chiatricGenomicsConsortiumleave-one-cohort-outPRSanaly-
ses for all SNP selection P value thresholds, which found the
median and the mode was P = .05, which represents the as-
sociation that best optimizes the balance of false and true risk
alleles at the current discovery sample size.21 Themost infor-
mative and independent markers were selected to minimize
statistical noise where possible, by using P value–informed
clumping at r2 < 0.2with 1-MBwindows andby excluding the
extendedmajor histocompatibility complex (chromosome 6:
position 25-35MB) because of its complex linkage disequilib-
rium structure.
OutcomeMeasure of Lifetime Psychosis
andMood Incongruence
Subtypes of BD
TheRDC subtypeswereused as categorical outcomes in case-
control analyses. The RDC3 and theDSM-5,2 although not the
International Statistical Classification of Diseases and Health-
RelatedDisorders,TenthRevision, Classification ofMental and
Behavioural Disorders,1 subdivides BD into bipolar I disorder
(BD I) and bipolar II disorder (BD II) depending on the nature
of themood states,mania in BD I, andhypomania in BD II. All
classification systems recognize SABD. Psychotic symptoms
aremostprominent inSABDand thenBD Iandare leastpromi-
nent in BD II.53,54
Bipolar Affective Disorder Dimension Scale
Outcome measures were generated from the Bipolar Affec-
tive Disorder Dimension Scale (BADDS) subscales of psycho-
sis andmood incongruence,whichprovideanordered,butnot
necessarily linear, measure of lifetime symptom domain
severity.55An interrater reliabilityexercise for this sampledem-
onstrates excellent interclass correlation: (psychosis) 0.91 and
(mood incongruence) 0.89.
1. A binary categorical outcome measure for lifetime occur-
rence of psychosis, defined as an unambiguous episode of
positive and/or disorganized psychotic symptoms, gener-
atedbydichotomizing thepsychosisdomain scale at a score
higher than 9.55
2. A binary categorical outcome measure for lifetime occur-
rence of predominant mood-incongruent psychotic fea-
tures, defined as high or low prominence of mood incon-
gruence, generated by dichotomizing the mood
incongruence domain scale at a score higher than 19.
3. An ordinal measure of mood-incongruent psychotic fea-
tures that assesses the overall balance between mood-
congruent andmood-incongruentpsychosis across the life-
time, rated using all available information according to the
BipolarDisorderResearchNetworkprotocol (see eNote 1 in
the eAppendix in the Supplement).
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Statistical Analysis
Amultinomial logitmodelwasused toestimatedifferential as-
sociationsof standardizedPRSs, adjusted for the first 10princi-
palcomponentsandgenotypingplatformsacross thecategories
of casesandcontrols.Wereport theestimatedcoefficient trans-
formed to relative risk ratio (RR), definedas the exponentiated
regressioncoefficient. In addition,PRSassociationsacross lev-
elsofmood-incongruentpsychotic featuresusingordinal logis-
tic regression were estimated. To examine whether SABD
subtypes were driving observed PRS associations with mood-
incongruentpsychotic features,wedidasensitivityanalysis that
excludedSABDcases.Postestimationpredictedprobabilitieswere
plotted toaid the interpretationofPRSassociationsacrossRDC
subtypesofBD.56Tocorrect formultiplecomparisonsofPRSas-
sociationsacrossdifferentphenotypicstratawithineachmodel,
we generated bootstrapped SEs and 95%CIs as an approxima-
tiontoexactpermutationmethods57 (seeeNote2intheeAppen-
dix in theSupplement). Possible familywise, type I errorprolif-
erationwascontrolledusing theBonferronimethod,calculated
bymultiplying the bootstrapped P values by 4.58
Post hoc analyses used a multinomial logit model case-
controldesign toexaminedifferential associationsacross com-
positephenotypiccategoriesdefinedbyBDIandBDII subtypes
andstratifiedbypsychosisstatus.Complementarylogisticregres-
sion analyses were conducted to compare the PRS association
with lifetimeoccurrenceofpsychosis acrossBD IandBDII sub-
types.Toexamine thedistributionofRDC-definedcasesacross
PRS levels, we converted the PRSs to deciles and generated a
stacked bar chart (SCZ [CLOZUK], SABD, BD I, BD II), by decile.
AnalyseswereperformedusingPLINK,version1.959(Christopher
Chang), or Stata, version 14 (StataCorp, LLC).
Results
Sample Description, Genotyping, and Quality Control
Of the 4436 cases of BD, 2966 (67%)were female patients, and
themean (SD) age at the SCAN interviewwas 46 [12] years. Af-
terBD,CLOZUK,andcontrol imputed-genotypedsampleswere
mergedandfurtherQCwasperformed,18387casesandcontrols
(eTable 1 in theSupplement)with3451354SNPs,withan infor-
mationcontentscorehigherthan0.8andaMAFgreater than1%,
were available for analysis. Within the BD sample, 2296 cases
(52%)endorsed lifetimeoccurrenceofdefinitepsychosis,with
less thana1%missingnessrate inthisvariable (n = 25).Of theBD
caseswithdefinitepsychosis, 981 (43%)were classifiedashav-
ing high lifetimemood-incongruent psychotic features. There
wasa9%missingness rate (n = 214) for themood-incongruence
variablewithin the BD caseswith psychosis.
Case-Control PRS Associations
As expected, the PRSs discriminated CLOZUK from control
samples (Table 1). The PRSs in thosewith a diagnosis of SABD
or BD I, but not BD II, were significantly higher than the PRSs
incontrols.Across clinicalphenotypes, therewasanexposure-
response gradient, with the strongest PRS association for
Table 1. Differential Association of Polygenic Risk Scores Across Variously Defined Bipolar Disease Strata
(Controls as Comparator Category)
Case
No. of Cases
(Subsample)
Relative Risk
Ratioa
Bootstrapped
P Value
Bonferroni-Corrected
P Value
Bootstrapped
95% CI
CLOZUK 4976 1.94 <.001 <.001 1.86-2.01
Bipolar Disorder Cases Stratified by RDC-Defined Subtypes
SABD 356 1.37 <.001 <.001 1.22-1.54
BD I 2775 1.30 <.001 <.001 1.24-1.36
BD II 1268 1.04 .26 .26 0.97-1.11
Bipolar Disorder Cases Stratified by LEP
No LEP 2079 1.09 .001 .004 1.04-1.15
LEP 2296 1.36 <.001 <.001 1.29-1.43
Psychotic Bipolar Disorder Cases Stratified by Level of Mood Incongruence
Low LMI 1126 1.24 <.001 <.001 1.17-1.33
High LMI 981 1.46 <.001 <.001 1.36-1.57
Sensitivity Analysis: Psychotic Bipolar Disorder Cases Stratified by Level of Mood Incongruence (Excluding SABD Cases)
Low LMI 1068 1.25 <.001 <.001 1.16-1.33
High LMI 699 1.49 <.001 <.001 1.37-1.62
Abbreviations: BD I, bipolar I disorder
subtype; BD II, bipolar II disorder
subtype; CLOZUK, treatment-
resistant schizophrenia treated with
clozapine study; LEP, lifetime ever
occurrence of psychotic symptoms;
LMI, lifetime pattern of low or high
mood incongruent psychotic
features; RDC, Research Diagnostic
Criteria; SABD, schizoaffective bipolar
disorder.
a Adjusted for polygenic risk score for
the first 10 principal components
and genotyping platforms.
Table 2. Polygenic Risk Scores for Schizophrenia Associations Among Cases
Case
Relative
Risk Ratioa
Bootstrapped
P Value
Bonferroni-Corrected
P Value
Bootstrapped
95% CI
SABD compared with TRS 0.71 <.001 <.001 0.63-0.80
BD I compared with TRS 0.67 <.001 <.001 0.64-0.71
BD II compared with TRS 0.54 <.001 <.001 0.50-0.57
SABD compared with BD II 1.32 <.001 <.001 1.16-1.50
BP I compared with BD II 1.25 <.001 <.001 1.16-1.35
SABD compared with BD I 1.05 .41 .41 0.93-1.18
Abbreviations: BD I, bipolar I disorder
subtype; BD II, bipolar II disorder
subtype; SABD, schizoaffective
bipolar disorder; TRS,
treatment-resistant schizophrenia.
a Adjusted for polygenic risk score for
the first 10 principal components
and genotyping platforms.
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schizophrenia (RR = 1.94;95%CI, 1.86-2.01), followedby schi-
zoaffective BD (RR = 1.37; 95% CI, 1.22-1.54), BD I (RR = 1.30;
95% CI, 1.24-1.36), and BD II (RR = 1.04; 95% CI, 0.97-1.11).
PRS AssociationsWithin Cases
The PRSs discriminated SCZ from all BD subtypes (Table 2).
Within BD, the PRSs discriminated BD II from both BD I and
SABD (Figure 1). The percentage of CLOZUK cases increased
monotonically with increasing decile of PRS, while the per-
centage of bipolar subtypes decreased (Figure 2).
PRS AssociationsWith Psychotic BD
Compared with controls, the PRSs were higher in BD, regard-
less of whether there was a history of psychosis (Table 1 and
Figure 2). However, the PRSs were significantly higher in BD
withpsychosis, comparedwithBDwithout psychosis (Table 1
andFigure 3).WithinBDcases, PRSsdiscriminated thosewith
andwithout psychosis (RR = 1.25; 95%CI, 1.16-1.33;P < .001).
Posthocanalyses showedtheassociationbetweenPRSand
psychosiswaspresent inBDI(oddsratio[OR] = 1.21;95%CI,1.10-
1.32)butwasnotstatisticallysignificant inBDII (OR = 0.98;95%
CI,0.80-1.18).Thecompositesubgroup,definedasBDIwithpsy-
chosis, had higher PRSs compared with the PRSs in controls
(RR = 1.38;95%CI, 1.31-1.46).This associationwassignificantly
stronger than that of the composite BD I without psychosis
(RR = 1.16;95%CI, 1.08-1.25).WithinBD II, therewasnodiffer-
ential associationacross subgroups,definedbypresenceor ab-
senceofpsychosis,ascomparedwiththedifferentialassociation
in controls (eTable 2 in the Supplement).
PRSAssociationsWithMood-IncongruentPsychoticFeatures
Psychotic BD characterized by high mood incongruence had
a higher SCZ polygenic risk burden than that in controls,
with a 1-SD increase in PRS increasing the RR of being in the
high mood-incongruence category by 46% (RR = 1.46; 95%
CI, 1.36-1.57) (Figure 3 and Table 1). Although the associa-
tion was significantly weaker than for the high mood-
incongruent group, SCZ risk alleles were enriched in those
with low mood-incongruence, compared with controls
(RR = 1.24; 95% CI, 1.17-1.33). Sensitivity analysis excluding
the SABD group from analyses found comparable results
(Table 1). Finally, a within-BD case analysis, measuring
mood incongruence on an ordinal scale, found the odds of
having higher levels of mood incongruence increased with
increasing PRS (OR = 1.17; 95% CI, 1.08-1.27; P < .001).
Analyses excluding the SABD sample found comparable
results (OR = 1.20; 95% CI, 1.09-1.32; P < .001).
Figure 2. Percentage of Bipolar Subtype as a Function
of Polygenic Risk Scores for Schizophrenia, Grouped by Decile
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Figure 3. Relative Risk Ratios for Schizophrenia and Bipolar Subtypes
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Figure 1. Probability of RDC Bipolar Subtype as a Function
of Polygenic Risk Scores (PRSs) AssociatedWith Schizophrenia
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Discussion
HigherPRS-SCZ inBD20,60 iswellestablished.Here,wereplicate
andextendthisobservation,demonstratingagradientofPRSas-
sociationsacrossSCZandBDsubtypes(CLOZUK>SABD>BDIwith
psychosis>BDIwithoutpsychosis>BDII). Inaddition,weshow
that BD cases with psychosis carry a higher burden of SCZ risk
alleles, compared with BD without a history of psychosis
(RR = 1.09;95%CI,1.04-1.15).Furthermore, individualswithpsy-
chotic BD characterized by prominent mood-incongruent
psychotic featurescarrythehighestburdenofschizophreniarisk
alleles.Thereisaclearexposure-responsegradient,withincreas-
ing PRS associatedwith psychotic BD and increasingmood in-
congruence(moodincongruent > moodcongruent > nopsycho-
sis),supportingourhypothesisthatmood-incongruenceindexes
phenotypic features linked to SCZ liability.
Previously published work examining the PRSs for SCZ
across BD, stratified by psychosis, did not find significant
discrimination,22,40 althougha trendwasobserved that is con-
sistentwith the findingspresentedhere.Themost likelyexpla-
nations for theenhancedsignal in thecurrentanalysisareas fol-
lows: the PRSs were constructed using alleles derived from a
largerSCZ-GWASdiscoveryset,whichreducesthemeasurement
error and improvespower fromboth this sampleand the larger
BD sample.61 This group has shown that PRS-SCZ significantly
differentiatesSABDfromnon-SABDsubtypes,while findingno
statistically significant differential between BD stratified by
psychosis,40 suggesting it is the nature of the psychotic symp-
toms rather than their presence thatbetter indexes the liability
sharedwithSCZ.62Thecurrentanalysissupportstheproposition
that it is thelevelofmoodincongruenceratherthanthepresence
ofpsychosis thatbetter specifiesa sharedbiologicallyvalidated
dimensional trait, which is captured, althoughwith less preci-
sion, by the SABDdiagnostic category.
Psychosis and mood-incongruent psychotic features are
known to be correlated with poorer prognosis and treatment
response.30-32 It is possible the transdiagnostic exposure-
response gradient for the PRS, with the occurrence and na-
ture of psychotic symptoms presented here, could be the re-
sult of a general psychopathological factor that cuts across
psychiatric disorders and influences the severity of psycho-
pathology generally as well as, or rather than, a psychosis-
specific domain. The PRS derived from SCZ-GWASmay be in-
dexing a general liability for psychopathological severity (at
least in part)63 rather than a (SCZ) disease-specific liability.
Implications
Our study supports the hypothesis that, within BD, positive
and disorganized psychotic symptoms—particularly, mood-
incongruentpsychotic features—represent adimensionallyde-
finedstratumwithunderpinningbiological validity.These fea-
tures are not only phenotypically similar to those observed in
prototypal SCZbut also indexagreater shared-genetic liability,
which suggests BD and SCZ share more pathophysiological
features.64Notably, inthosediagnosedwithBDIwithnohistory
of psychosis, the associationwith SCZ liabilitywasweaker but
still higher than in the control group, while therewas no over-
lapwithSCZ liability in theBDII subsample.Wearenotsuggest-
ingthatpsychoticfeaturesarethebestortheonlyindexofshared
pathophysiological features,buthavingestablishedstrongerge-
netic linksbetweenthe risk forSCZandBDcharacterizedby the
occurrenceofpsychosisandlevelofmoodincongruence,wenow
haveabasis to refine this signal.These findings representa step
towardthegoalofreconceptualizingphenotypicdefinitionsusing
richerclinical signatures,measuredacrossquantitativeorquali-
tativedomains, including symptom loadingandbiomarker ex-
pression,outlined in therationale for theRDC65,66andtheRoad
MapforMentalHealthResearch inEurope67projects.However,
amultidimensional stratificationprocesswill likelyharness the
observedclinical heterogeneitybetter anddefinemoreprecise
patient strataor subgroups in closer alignmentwith theunder-
lying biologicalmechanisms.68-70
Limitations
Phenotypicmisclassification isapotentialmethodological con-
cern.However, thephenotypic ratingsusedinthecurrentanaly-
sesarebasedonboth theSCANinterviewandcase-note review
by raterswith excellent interrater reliability,which is expected
tominimize ratesofmissingdataanddifferentialmisclassifica-
tionduetorecallbiasofpsychoticsymptoms.70It ispossible that
differentialmisclassificationofmood incongruencemaystill be
present. Thepsychosis phenotypes examined in this study are
broadlydefinedandlikelytorepresent imperfectmeasurements
of aphenotype thatmaybe continuouslydistributed71; impos-
ing categorical constraints aswehavedonemay reducepower.
Multipletestingcanproducespuriousresults; thus,toreducethis
likelihoodwegeneratedPRSsusingasinglediscovery-setthresh-
oldofP < .05.Bootstrapresamplingapproacheswereusedwithin
each of the 4 independent analyses to dealwithmultiple com-
parisons acrossdifferentphenotypic strata. Bonferroni correc-
tionwasused toadjust forpossible familywise type I errorpro-
liferation. The PRSs were generated using the most probable
genotypes that can potentially reduce power due to a (nondif-
ferential) lossof informationatsomemarkers,makingourresults
conservative.Casesandcontrolswerecollected independently,
whichcanresult inconfoundingduetopopulationstratification
andpotentialbatcheffectsacrossthecasesandcontrols.Wemiti-
gatedagainst thisbypartiallingout the first 10principal compo-
nents and genotyping platforms from the PRS, but some con-
founding is still possible. Finally, we have only examined the
effect of commonvariants, as rare variants arenot capturedby
current GWAS.
Conclusions
To our knowledge, this study is the first to show a gradient of
polygenic liability across SCZ and BD, indexed by the occur-
rence and level of mood incongruence of positive and disor-
ganizedpsychotic symptoms. These results highlight theuse-
fulness of genetic data todissect clinical heterogeneitywithin
and across disorders and suggest further research could po-
tentially aid in defining patient stratifiers with improved bio-
logicalprecisionandvalidity,movingus tentatively towardpre-
cision medicine in psychiatry.
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